In hepatocellular carcinoma cells, LicoA was shown to inhibit the activity, migration, and invasion of urokinase-type plasminogen activator (uPA) by targeting the binding ability of NF-κB to the uPA promoter in the MKK4/JNK-dependent pathway [42]. Here, MAP2K4 is linked to hepatocellular carcinoma.